New TAVI Head-To-Head: Sapien XT Vs. Surgery-Superior CoreValve
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences will bring its next-generation transcatheter aortic valve implant (TAVI) system, Sapien XT to the U.S. just in time to face the growing threat of competition from Medtronic’s CoreValve, which earned an expanded FDA indication for patients at high risk for surgery.
You may also be interested in...
US FDA Green-Lights Medtronic's CoreValve Evolut For Intermediate Risk
The approval, based on the results of the SURTAVI trial, comes a few months ahead of analysts' expectations and is welcome news for Medtronic in its effort to keep pace with TAVR leader Edwards in the US market.
Edwards Reports TAVR Sales Progress In U.S. And Abroad
Edwards Lifesciences reported 19 percent year-over-year growth in worldwide sales of its Sapien transcatheter aortic valve systems during the second quarter of 2014. The company cites the ongoing launch of the Sapien 3 system in Europe and Sapien XT in the U.S. as keys to continuing growth.
TAVR Evolution On Display At EuroPCR
Data on both new transcatheter aortic valve technologies and established TAVR devices were featured at this year’s EuroPCR meeting in Paris.